|
|
|
|
|
|
|
We have just release the Annual Report for 2022, we are on to a really good track and very excited about the future. Thanks to a great effort by the team!
|
|
|
|
|
|
Annual Report 2022
|
|
|
During 2022 we made much progress with our clinical development and CMC & Device activities, setting the foundation for a news-rich 2023 year ahead. As well as reporting positive top line results from 0204 and 0206 we began our pivotal study 0205. Recruitment for this study is now well underway and we look forward to announcing data from this study later in 2023.
|
|
|
|
|
Why Cessatech and why now?
We have two main tasks for 2023:
|
-
|
Complete the pivotal clinical study 0205 and study 0202
|
-
|
Finalise the commercial business setup for Europe and US
|
|
|
|
|
|
|
|
AT LATE-STAGE DEVELOPMENT
|
|
Pipeline update
|
|
During 2023 we will give more updated on the remaining clinical trials and our accomplicements...
|
|
|
|
|
|
|
|
Massive presence of off-label medicines in Danish departments
|
|
A nationwide survey using national hospital purchase data.
|
|
|
|
|
|
|
|
In 2022 the first patient was dosed in pivotal trial (0205) in adult patients - this trial investigates the postoperative analgesic efficacy of CT001.
|
|
|
|
|
|
|
|
Financials including 2022 results
|
|
|
|
|
|
Cessatech management team
|
|
|
|
|
|
|
Shareholders
|
|
Management, Board of Directors and other Insiders.
|
|
|
Together currently hold 16%
|
|
|
|
|
|
|
|
|
FOR PAIN TREATMENT OF CHILDREN.
|
|
|
Studies show that of label use of medication is the rule rather than the exception and that 79% of the emergency rooms in Scandinavia use physical restraint on children.
|
|
|
Cessatech aims to meet that need – and the first product and lead asset, CT001, is a nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures.
|
|
|
Drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a good effect can be documented. Thus offering economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile.
|
|
|
|
|
|
